Glucagon-Like Peptide-1 Receptor Agonist Therapy for Failed Weight Loss Surgery

Authors

• Sean Bannister, University of LynchburgFollow

Specialty

Surgery

Advisor

Dr. Charan Donkor

Abstract

This review evaluates the effectiveness of glucagon-like peptide-1 receptor agonist therapies (GLP-1 RAs) as a noninvasive alternative weight loss strategy to revisional bariatric surgery (RBS) for failed metabolic bariatric surgery (MBS). A comprehensive search of electronic databases was conducted, where 12 studies were identified assessing the weight loss effects of GLP-1 RAs compared to MBS, and the effectiveness of GLP-1 RAs and RBS for the treatment of failed weight loss surgery. Failure is characterized by insufficient weight loss (IWL) or failure to lose a significant percentage of total body weight (TBW), or weight regain (WR) or regain of significant weight after reaching the postoperative goal. The findings suggest that although MBS has been firmly established as the treatment of choice for significant obesity there is a failure rate of up to 33%. Newer GLP-1 RAs achieve TBW loss of up to 25.3%, nearing that of MBS, offering a potent and noninvasive alternative to RBS. The paucity of well-designed long-term randomized controlled trials (RCTs) comparing GLP-1 RAs and RBS head-to-head for the treatment of failed MBS calls attention to the need for further research to establish the effectiveness of pharmacological therapy and develop standardized protocols for implementation. The review highlights the efficacy of the newest class of weight loss medications and their ability to effectively initiate or restart weight loss after failed weight loss surgery. Novel strategies using GLP-1 RAs have the potential to transform obesity management and offer a safer and more accessible pathway for patients experiencing surgical failure.

Recommended Citation

Bannister S. Glucagon-Like Peptide-1 Receptor Agonist Therapy for Failed Weight Loss Surgery. University of Lynchburg DMSc Doctoral Project Assignment Repository. 2026; 8(1).